Medscape recently featured a set of findings from the MIND program which were published in JAMA psychiatry last week! Although it is often assumed individuals using hemp-derived products will test negative for THC, 50% of study participants enrolled in the open label phase of our clinical trial tested positive on a urine drug screen after four weeks of using the full-spectrum high CBD product. This occurred even though the product contained far less THC than is legally allowable for hemp-based products in the US, and occurred despite the fact that no individuals reported feeling high or intoxicated when using the product. Accordingly, results suggest some individuals who consistently use hemp-based products, which are legal in the US, may be at risk for adverse legal consequences.